Equities

908 Devices Inc.

MASS:NMQ

908 Devices Inc.

Actions
Health CareMedical Equipment and Services
  • Price (USD)5.65
  • Today's Change-0.02 / -0.35%
  • Shares traded254.03k
  • 1 Year change-13.74%
  • Beta1.0186
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

908 Devices Inc. offers a suite of purpose-built handheld and desktop mass spectrometry (Mass Spec) devices for the point of need chemical and biochemical analysis. The Company's Mass Spec devices are used at the point of need to interrogate unknown and invisible materials and provide answers to address problems in life sciences research, bioprocessing, industrial biotechnology, forensics and adjacent markets. Its products include MX908, Rebel, ZipChip, Maven and Maverick. MX908 is a handheld, battery-powered, Mass Spec device designed for the analysis of solid, liquid, vapor and aerosol materials of unknown identity. MX908 is a multi-purpose device utilized by a spectrum of user segments for a variety of forensic field applications, including chemical, explosive, priority drug and hazardous materials operations, detecting materials at the trace level. The Rebel is a small desktop analyzer providing real-time information on the extracellular environment in bioprocesses.

  • Revenue in USD (TTM)50.23m
  • Net income in USD-36.40m
  • Incorporated2012
  • Employees230.00
  • Location
    908 Devices Inc.645 Summer StreetBOSTON 02210United StatesUSA
  • Phone+1 (978) 729-4478
  • Fax+1 (302) 655-5049
  • Websitehttps://908devices.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Owlet Inc54.01m-37.49m37.65m76.00------0.6971-4.54-4.546.53-3.371.062.513.61710,657.90-64.37------41.82---60.92--0.7419-8.97-----21.95--52.74------
Clearsign Technologies Corp2.40m-5.19m39.49m15.00--6.41--16.43-0.1350-0.13500.06240.13420.2592--8.37160,200.00-56.02-61.67-68.60-69.4334.005.94-216.15-1,010.99----0.00--542.5135.309.80---16.81--
BioNano Genomics Inc36.12m-232.49m49.67m344.00--0.452--1.38-6.78-6.781.062.100.13841.014.42104,988.40-89.09-56.82-120.46-67.8326.4825.38-643.74-505.761.17-76.350.0386--29.9024.65-75.34--38.51--
Fossil Group Inc1.41bn-157.09m53.02m6.10k--0.2085--0.0375-3.00-3.0027.014.841.272.317.17231,538.40-14.14-4.59-21.56-7.2448.5149.48-11.09-3.631.34-4.230.4518---16.05-11.09-255.75---13.84--
Midwest Energy Emissions Corp17.94m5.90m72.59m9.0015.11--11.864.050.0510.0510.1841-0.00830.974813.637.161,993,376.0032.08-21.6537.61-47.8132.1532.8032.91-15.5710.70-6.191.08---17.027.85473.32------
Babcock & Wilcox Enterprises Inc999.35m-93.73m96.64m2.20k------0.0967-1.05-2.3811.22-2.251.167.165.30454,251.80-9.16-5.50-15.81-11.8722.4222.90-7.87-5.301.100.50611.97--17.86-1.22-201.13--12.36--
Luna Innovations Inc116.61m-1.12m103.91m337.00--1.1023.480.8911-0.0339-0.06373.452.790.75151.262.84346,035.60-0.72310.8556-0.92921.0959.0056.43-0.96221.231.620.13660.25210.0025.1227.05-111.20--16.38--
Seer Inc16.66m-86.28m145.46m147.00--0.3629--8.73-1.35-1.350.26096.170.03611.792.43113,340.10-18.67-16.65-19.21-17.0951.05---517.84-756.7124.66--0.00--7.54--7.20--112.67--
Harvard Bioscience, Inc.112.25m-3.42m167.17m391.00--2.2946.661.49-0.0803-0.08032.631.680.79411.816.84287,084.40-2.42-3.29-2.93-3.8958.8656.67-3.04-4.570.91640.44850.3335---0.9573-1.4564.11--18.10--
Geospace Technologies Corp143.43m24.98m167.80m681.006.741.154.091.171.871.8710.7610.990.9383.764.35210,619.7016.34-5.1018.55-5.5444.2028.7017.42-8.963.79--0.00--39.5010.45153.40--11.01--
Northern Technologies International Corp82.70m3.66m168.28m86.0047.332.4624.612.030.37720.37728.617.250.95373.765.27961,669.605.886.297.447.7137.0133.216.167.421.86--0.052453.377.759.21-53.95-16.8734.3913.30
Virtra Inc38.04m8.40m183.53m112.0021.594.3119.674.820.76530.76533.473.840.61631.032.78339,672.8013.617.6917.169.7070.0959.0622.0911.122.32--0.1587--34.4216.04329.6259.3430.96--
908 Devices Inc.50.23m-36.40m185.94m230.00--1.11--3.70-1.13-1.131.565.090.22551.815.28218,387.00-16.34-14.16-18.03-15.3550.4153.02-72.47-64.257.04--0.00--7.2117.89-8.45--22.98--
Data as of May 03 2024. Currency figures normalised to 908 Devices Inc.'s reporting currency: US Dollar USD

Institutional shareholders

49.99%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 31 Mar 20244.05m12.30%
Granahan Investment Management, LLCas of 31 Dec 20232.04m6.20%
Columbia Management Investment Advisers LLCas of 31 Dec 20231.89m5.74%
The Vanguard Group, Inc.as of 31 Dec 20231.72m5.24%
Eventide Asset Management LLCas of 31 Dec 20231.43m4.35%
BlackRock Fund Advisorsas of 31 Dec 20231.39m4.21%
Iron Triangle Partners LPas of 31 Dec 20231.28m3.90%
Fred Alger Management LLCas of 31 Dec 20231.21m3.68%
Platinum Investment Management Ltd.as of 31 Dec 2023781.87k2.38%
AWM Investment Co., Inc.as of 31 Dec 2023653.47k1.99%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.